Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230487244> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4230487244 endingPage "3129" @default.
- W4230487244 startingPage "3116" @default.
- W4230487244 abstract "A highly aggressive human CALLA+C mu+ pre-B acute lymphoblastic leukemia (ALL) cell line (NALM-6-UM1) causes disseminated and invariably fatal leukemia in CB.17 mice with severe combined immunodeficiency (SCID). We used this SCID mouse model of human pre-B ALL to evaluate and compare, in a total of 434 SCID mice, the antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and cyclophosphamide (CPA) as individual reagents and as combined immunochemotherapeutic regimens. B43-PAP plus CPA was superior to either the immunotoxin or drug alone, and combined immunochemotherapy markedly improved the event-free survival (EFS) of SCID mice challenged with NALM-6-UM1 pre-B ALL cells. Notably, 90% to 100% of SCID mice challenged with 1 x 10(6) leukemia cells and then treated with B43-PAP plus CPA combined immunochemotherapy regimens became long-term survivors, a result not achieved with B43-PAP alone or CPA alone. The advantage was particularly evident in mice inoculated with 5 x 10(6) leukemia cells. While neither 15 micrograms B43-PAP (median survival, 58 days) nor 1 mg CPA (median survival, 49 days) resulted in long-term EFS of SCID mice challenged with 5 x 10(6) NALM-6- UM1 pre-B ALL cells, the probability of EFS at 6 months was 50% +/- 16% for SCID mice treated with 15 micrograms B43-PAP plus 1 mg CPA (median survival, greater than 180 days) (P less than .0001). The probability of long-term EFS was only 14% +/- 7% for mice treated with 30 micrograms B43-PAP and 0% +/- 0% for mice treated with 1 mg CPA, but 40% +/- 16% for mice treated with 30 micrograms B43-PAP plus 1 mg CPA (P less than .0001). Similarly, the probability of EFS at 6 months was 40% +/- 16% for mice treated with 2 mg CPA alone, 70% +/- 15% for mice treated with 2 mg CPA plus 15 micrograms B43-PAP, and 70% +/- 15% for mice treated with 2 mg CPA plus 30 micrograms B43-PAP. Ten SCID mice in the B43-PAP plus CPA combined immunochemotherapy arms surviving long term after the inoculation of 5 x 10(6) NALM-6-UM1 pre-B ALL cells were electively killed at 174 to 181 days to assess their leukemia burden. We found no evidence of leukemia in any of the bone marrow specimens by two-color immunofluorescence and multiparameter flow cytometry.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
- W4230487244 created "2022-05-11" @default.
- W4230487244 creator A5008674365 @default.
- W4230487244 creator A5009387654 @default.
- W4230487244 creator A5027934295 @default.
- W4230487244 creator A5038801007 @default.
- W4230487244 creator A5046062964 @default.
- W4230487244 creator A5065535718 @default.
- W4230487244 creator A5075134577 @default.
- W4230487244 creator A5091381226 @default.
- W4230487244 date "1992-06-15" @default.
- W4230487244 modified "2023-10-16" @default.
- W4230487244 title "Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide" @default.
- W4230487244 doi "https://doi.org/10.1182/blood.v79.12.3116.bloodjournal79123116" @default.
- W4230487244 hasPublicationYear "1992" @default.
- W4230487244 type Work @default.
- W4230487244 citedByCount "31" @default.
- W4230487244 countsByYear W42304872442013 @default.
- W4230487244 countsByYear W42304872442015 @default.
- W4230487244 crossrefType "journal-article" @default.
- W4230487244 hasAuthorship W4230487244A5008674365 @default.
- W4230487244 hasAuthorship W4230487244A5009387654 @default.
- W4230487244 hasAuthorship W4230487244A5027934295 @default.
- W4230487244 hasAuthorship W4230487244A5038801007 @default.
- W4230487244 hasAuthorship W4230487244A5046062964 @default.
- W4230487244 hasAuthorship W4230487244A5065535718 @default.
- W4230487244 hasAuthorship W4230487244A5075134577 @default.
- W4230487244 hasAuthorship W4230487244A5091381226 @default.
- W4230487244 hasBestOaLocation W42304872441 @default.
- W4230487244 hasConcept C115085202 @default.
- W4230487244 hasConcept C126322002 @default.
- W4230487244 hasConcept C150903083 @default.
- W4230487244 hasConcept C159047783 @default.
- W4230487244 hasConcept C159654299 @default.
- W4230487244 hasConcept C203014093 @default.
- W4230487244 hasConcept C207001950 @default.
- W4230487244 hasConcept C2776694085 @default.
- W4230487244 hasConcept C2776755627 @default.
- W4230487244 hasConcept C2777820912 @default.
- W4230487244 hasConcept C2778461978 @default.
- W4230487244 hasConcept C2778957590 @default.
- W4230487244 hasConcept C2779468541 @default.
- W4230487244 hasConcept C2781107101 @default.
- W4230487244 hasConcept C2909962599 @default.
- W4230487244 hasConcept C542903549 @default.
- W4230487244 hasConcept C71924100 @default.
- W4230487244 hasConcept C86803240 @default.
- W4230487244 hasConceptScore W4230487244C115085202 @default.
- W4230487244 hasConceptScore W4230487244C126322002 @default.
- W4230487244 hasConceptScore W4230487244C150903083 @default.
- W4230487244 hasConceptScore W4230487244C159047783 @default.
- W4230487244 hasConceptScore W4230487244C159654299 @default.
- W4230487244 hasConceptScore W4230487244C203014093 @default.
- W4230487244 hasConceptScore W4230487244C207001950 @default.
- W4230487244 hasConceptScore W4230487244C2776694085 @default.
- W4230487244 hasConceptScore W4230487244C2776755627 @default.
- W4230487244 hasConceptScore W4230487244C2777820912 @default.
- W4230487244 hasConceptScore W4230487244C2778461978 @default.
- W4230487244 hasConceptScore W4230487244C2778957590 @default.
- W4230487244 hasConceptScore W4230487244C2779468541 @default.
- W4230487244 hasConceptScore W4230487244C2781107101 @default.
- W4230487244 hasConceptScore W4230487244C2909962599 @default.
- W4230487244 hasConceptScore W4230487244C542903549 @default.
- W4230487244 hasConceptScore W4230487244C71924100 @default.
- W4230487244 hasConceptScore W4230487244C86803240 @default.
- W4230487244 hasIssue "12" @default.
- W4230487244 hasLocation W42304872441 @default.
- W4230487244 hasOpenAccess W4230487244 @default.
- W4230487244 hasPrimaryLocation W42304872441 @default.
- W4230487244 hasRelatedWork W1575485051 @default.
- W4230487244 hasRelatedWork W187054041 @default.
- W4230487244 hasRelatedWork W1984122251 @default.
- W4230487244 hasRelatedWork W2104736722 @default.
- W4230487244 hasRelatedWork W2165706358 @default.
- W4230487244 hasRelatedWork W2169441459 @default.
- W4230487244 hasRelatedWork W2415465271 @default.
- W4230487244 hasRelatedWork W2417659772 @default.
- W4230487244 hasRelatedWork W4230487244 @default.
- W4230487244 hasRelatedWork W1838376532 @default.
- W4230487244 hasVolume "79" @default.
- W4230487244 isParatext "false" @default.
- W4230487244 isRetracted "false" @default.
- W4230487244 workType "article" @default.